Breaking News

You are here » Indian-Commodity  :  Corporate  :  Bhushan Steel turns black in Q1FY19

10-Aug2018

Bhushan Steel turns black in Q1FY19

Bhushan Steel has reported results for first quarter ended June 30, 2018.

The company has reported a net profit at Rs 2,104.30 crore for the quarter under review as against net loss of Rs 1,486.13 crore for the same quarter in the previous year. Total income of the company increased by 10.73% at Rs 4,646.15 crore for Q1FY19 as compared Rs 4,196.10 crore for the corresponding quarter previous year.

Bhushan Steel is one of the prominent players in the Indian Steel industry. Backed with more than 27 years of experience, the company is India's 3rd largest Secondary Steel Producing Company with an existing steel production capacity of 5.6 million ton per annum.


Related News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......